Cynomolgus STEAP1 VLP (STP-CM00V) Summary
Product Description |
Recombinant Cynomolgus STEAP1 VLP is expressed from HEK293.It contains Met1-Leu339 (It may have cross reaction with anti-His antibody). |
Product Background |
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface protein of the STEAP family whose main function focuses on intercellular communication and cell growth. STEAP1 is is associated with tumor invasiveness and progression. It is considered a promising putative biomarker and a candidate target for prostate cancer treatment. |
Product Category |
Recombinant Protein / Antibody discovery / Multiple transmembrane proteins / VLP |
Cynomolgus STEAP1 VLP (STP-CM00V) Specifications/Details
Protein |
STEAP1 |
Synonyms |
PRSS24; STEAP; PRSS24, STEAP 1 |
Accession |
|
Species |
Cynomolgus |
Biotinylated |
no |
Amino Acid Range |
Met1-Leu339 |
Molecular Weight |
The protein has a predicted MW of 43.1 kDa. |
Activity |
Immobilized Cynomolgus STEAP1 at 5 ug/ml (100ul/well) on the plate. Dose response curve for Vandortuzumab, hFc Tag with the EC50 of 36.7 determined by ELISA. |
Expression System |
HEK293 |
Purity |
> 95% as determined by HPLC |
Endotoxin |
Less than 1 EU per ug by the LAL method. |
Shipping, Reconstitution, & Storage
Form |
Liquid |
Shipping |
Shipped with dry ice. |
Formulation |
Supplied as 0.22 um filtered solution in PBS, 300mM L-arginine (pH 7.4). |
Stability And Storage |
Valid for 12 months from date of receipt when stored at -80°C.； Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Validation Images
|
|
Immobilized Cynomolgus STEAP1 at 5 ug/ml (100ul/well) on the plate. Dose response curve for Vandortuzumab, hFc Tag with the EC50 of 36.7 determined by ELISA. |
|
|
The purity of Cynomolgus STEAP1 VLP is greater than 95% as determined by SEC-HPLC. |
Related Products
Have more questions?
Check out our Frequently Asked Questions page for more details about product specifications, ordering, and shipments.
Contact Us
Recently viewed
